Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7955490 | 0.95 | PDE5A (0.90) | PDE5ANR3C1PDE4B | |
| SCHEMBL7954877 | 0.93 | PDE5A (0.87) | PDE5ANR3C1PDE4B | |
| SCHEMBL12551683 | 0.93 | PDE5A (0.86) | PDE5ANR3C1PDE4B | |
| SCHEMBL7955209 | 0.91 | PDE5A (0.84) | PDE5ANR3C1PDE4B | |
| SCHEMBL7096587 | 0.91 | PDE5A (0.83) | PDE5ANR3C1PDE4B | |
| SCHEMBL7956986 | 0.90 | PDE5A (0.82) | PDE5ANR3C1PDE4B | |
| SCHEMBL7947675 | 0.90 | PDE5A (0.82) | PDE5ANR3C1PDE4B | |
| SCHEMBL7948031 | 0.90 | PDE5A (0.82) | PDE5ANR3C1PDE4B | |
| SCHEMBL7958851 | 0.90 | PDE5A (0.81) | PDE5ANR3C1PDE4B | |
| SCHEMBL7947974 | 0.89 | PDE5A (0.81) | PDE5ANR3C1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6326379-B1 | ERECTILE DYSFUNCTION; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. | 2001-12-04 | — | — | US | claimed |
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| EP-1113796-A4 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6326379-B1 | ERECTILE DYSFUNCTION; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. | 2001-12-04 | — | — | US | disclosed |
| EP-1113796-A1 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015222-A1 | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216275-A1 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE5A, PDE4A | PDE5A 2/4885NR3C1 4150/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.